Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Kombinierte Ernährungs- und Bewegungsinterventionen bei Frauen mit Brustkrebsvorgeschichte

2. Oktober 2026 aktualisiert von: Prof. Dr. Alejandro Martínez-Rodríguez, University of Alicante

Studie zu den Auswirkungen der Umsetzung von diätetisch-ernährungsphysiologischen Strategien und eines Bewegungsprogramms auf physischer, physiologischer und psychologischer Ebene bei Frauen mit einer Vorgeschichte von Brustkrebs.

This study aims to evaluate the effects of a combined dietary-nutritional and physical exercise intervention on physical, physiological, and psychological outcomes in women who are breast cancer survivors. Participants will be randomly assigned to different intervention groups involving dietary modification, exercise training, or their combination, compared to a control group. The program will last 12 weeks and will include pre- and post-intervention assessments of body composition, metabolic parameters, functional capacity, and quality of life.

The primary goal is to assess improvements in physical fitness, body composition, and emotional well-being, as well as to identify potential synergistic effects of combined interventions in this population.

Studienübersicht

Status

Abgeschlossen

Bedingungen

Intervention / Behandlung

Detaillierte Beschreibung

Breast cancer survivors often experience long-term physical and psychological side effects derived from treatment, such as fatigue, loss of muscle mass, metabolic alterations, and reduced quality of life. Lifestyle interventions involving nutrition and exercise have demonstrated significant potential to mitigate these effects and promote overall recovery.

This randomized controlled clinical trial will include adult female breast cancer survivors who have completed their primary oncological treatment. Participants will be divided into six parallel groups:

  1. Control group - no intervention.
  2. Mediterranean diet group (MD) - individualized nutritional plan based on Mediterranean dietary patterns.
  3. Strength training group (ST) - supervised resistance exercise sessions.
  4. Endurance training group (ET) - supervised aerobic exercise sessions.
  5. Combined training group (CT) - combination of strength and endurance training.
  6. Combined diet and exercise group (MD+CT) - simultaneous application of Mediterranean diet and combined training.

The intervention will last 12 weeks, during which participants in the intervention groups will attend supervised sessions and receive continuous nutritional guidance. Assessments will be performed at baseline and after 12 weeks, including anthropometric and body composition analysis, metabolic and inflammatory markers, physical fitness testing, dietary intake, and psychological well-being scales.

This study seeks to identify the most effective strategy-dietary, physical, or combined-for improving health outcomes, functionality, and emotional recovery in breast cancer survivors, contributing to the development of comprehensive post-treatment rehabilitation programs.

Studientyp

Interventionell

Einschreibung (Tatsächlich)

120

Phase

  • Unzutreffend

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

    • Alicante
      • Elche, Alicante, Spanien, 03203
        • European Institute Of Exercise and Health

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

30 Jahre bis 65 Jahre (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Weiblich

Beschreibung

Inclusion Criteria:

  • Women aged 30 to 65 years.
  • Previous diagnosis of breast cancer (stages I-III) confirmed by medical records.
  • Completion of primary oncological treatment (surgery, radiotherapy, chemotherapy, and/or hormone therapy) at least 3 months before enrollment.
  • Absence of active cancer or evidence of recurrence.
  • Medical clearance to perform physical exercise.
  • Willingness to participate in dietary and/or exercise interventions for 12 weeks.
  • Ability to attend evaluation and intervention sessions and comply with study procedures.
  • Signed written informed consent.

Exclusion Criteria:

  • Active cancer, metastasis, or ongoing chemotherapy or radiotherapy.
  • Severe cardiovascular, respiratory, renal, hepatic, or metabolic disease that contraindicates exercise.
  • Musculoskeletal or neurological conditions limiting participation in physical activity.
  • Severe psychiatric disorders or cognitive impairment affecting adherence to the intervention.
  • Current participation in another clinical trial or structured lifestyle intervention.
  • Use of dietary supplements, appetite regulators, or pharmacological agents affecting metabolism during the study period.
  • Pregnancy, breastfeeding, or intention to become pregnant during the study.
  • Inability to comply with the intervention schedule or follow-up assessments.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Single

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Kein Eingriff: Arm 1 - Control Group

Participants will not receive any specific dietary or exercise intervention. They will be asked to maintain their usual lifestyle and dietary habits during the 12-week study period. General health recommendations based on national guidelines will be provided at baseline.

Experimental: Arm 2 - Mediterranean Diet Group (MD)

Participants will receive individualized nutritional counseling promoting adherence to a Mediterranean dietary pattern, emphasizing fruits, vegetables, legumes, whole grains, olive oil, nuts, fish, and moderate dairy intake. Processed and high-sugar foods will be limited. Dietitians will provide personalized follow-up and adjustments every two weeks to ensure adherence.

Individualized nutritional counseling based on Mediterranean diet principles, emphasizing the intake of fruits, vegetables, legumes, whole grains, nuts, olive oil, and fish, while reducing red meat, processed foods, and added sugars. Sessions will be held biweekly to ensure adherence and promote long-term dietary behavior change.

Experimental: Arm 3 - Strength Training Group (ST)

Participants will perform a 12-week supervised resistance training program focused on improving muscular strength and functional capacity. Sessions will be conducted three times per week, lasting approximately 60 minutes, and include major muscle groups using elastic bands, free weights, and bodyweight exercises. Training load will progressively increase according to individual capacity.

A structured resistance exercise program performed three times per week for 12 weeks. Each 60-minute session will include exercises for major muscle groups using elastic bands, dumbbells, or body weight, progressively increasing intensity to improve muscle strength and endurance.

Experimental: Arm 4 - Endurance Training Group (ET)

Participants will follow a structured aerobic exercise program consisting of walking, cycling, or treadmill sessions three times per week for 12 weeks. The intensity will be moderate (60-75% of estimated maximal heart rate), gradually progressing as tolerated. The goal is to enhance cardiorespiratory fitness and overall endurance.

A structured aerobic exercise program consisting of walking, cycling, or treadmill training three times per week for 12 weeks. Exercise intensity will range from 60% to 75% of the estimated maximal heart rate, progressively adjusted to enhance cardiovascular fitness and fatigue resistance.

Experimental: Arm 5 - Combined Training Group (CT)

Participants will perform both strength and aerobic training during the 12-week intervention. Each session (3 per week, 60-70 minutes) will include resistance exercises targeting major muscle groups followed by aerobic activity at moderate intensity. The program aims to improve both muscular and cardiovascular performance synergistically.

A combined exercise protocol including both resistance and aerobic components within each 60-70-minute session, three times per week for 12 weeks. Strength exercises will precede moderate-intensity aerobic work to improve overall physical performance and functional capacity.

Experimental: Arm 6 - Mediterranean Diet plus Combined Training Group (MD+CT)

Participants will simultaneously receive the Mediterranean Diet counseling and participate in the Combined Training program for 12 weeks. The objective is to assess the synergistic effects of diet and exercise on physical, physiological, and psychological health in breast cancer survivors.

Comprehensive lifestyle intervention combining Mediterranean diet counseling with the supervised combined training program. Participants will receive individualized diet plans and attend three supervised exercise sessions per week. The intervention targets improvements in body composition, physical fitness, and emotional well-being.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Change in Fat-Free Mass (kg)
Zeitfenster: Baseline and Week 12

To evaluate changes in fat-free mass after the 12-week intervention, measured by bioimpedance analysis (BIODY XPERT ZM).

Baseline and Week 12

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Change in Fat Mass (%)
Zeitfenster: Baseline and Week 12

To assess changes in total body fat percentage using bioimpedance analysis.

Baseline and Week 12
Change in Body Weight (kg)
Zeitfenster: Baseline and Week 12

To determine body weight variation during the 12-week intervention.

Baseline and Week 12
Change in Body Mass Index (kg/m²)
Zeitfenster: Baseline and Week 12

To evaluate changes in BMI calculated as weight divided by height squared.

Baseline and Week 12
Change in Waist Circumference (cm)
Zeitfenster: Baseline and Week 12

To assess central adiposity changes by measuring waist circumference.

Baseline and Week 12
Change in Handgrip Strength (kg)
Zeitfenster: Baseline and Week 12

To evaluate upper-body muscular strength using a digital hand dynamometer.

Baseline and Week 12
Change in Lower-Limb Strength (kg)
Zeitfenster: Baseline and Week 12

To assess lower-limb strength through isometric tests using a load cell or force platform.

Baseline and Week 12
Change in Functional Capacity (6-Minute Walk Test Distance, m)
Zeitfenster: Baseline and Week 12

To evaluate cardiorespiratory endurance using the 6-minute walk test.

Baseline and Week 12
Change in Balance Performance
Zeitfenster: Baseline and Week 12

To assess dynamic balance and postural control

Baseline and Week 12
Change in Flexibility (Sit-and-Reach Test, cm)
Zeitfenster: Baseline and Week 12

To evaluate flexibility of the posterior chain through the sit-and-reach test.

Baseline and Week 12
Change in Maximal Oxygen Uptake (VO₂max, mL/kg/min)
Zeitfenster: Baseline and Week 12

To determine changes in aerobic capacity using an incremental treadmill test with indirect calorimetry (METALYZ-ERR 3 B-R3 spirometer).

Baseline and Week 12
Change in Total Cholesterol (mg/dL)
Zeitfenster: Baseline and Week 12

To evaluate lipid profile variations by measuring total cholesterol concentration.

Baseline and Week 12
Change in HDL Cholesterol (mg/dL)
Zeitfenster: Baseline and Week 12

To assess cardioprotective lipid changes.

Baseline and Week 12
Change in LDL Cholesterol (mg/dL)
Zeitfenster: Baseline and Week 12

To measure changes in LDL cholesterol levels.

Baseline and Week 12
Change in Triglycerides (mg/dL)
Zeitfenster: Baseline and Week 12

To determine variations in triglyceride concentration.

Baseline and Week 12
Change in Fasting Glucose (mg/dL)
Zeitfenster: Baseline and Week 12

To assess metabolic health by measuring fasting plasma glucose.

Baseline and Week 12
Change in C-Reactive Protein (mg/L)
Zeitfenster: Baseline and Week 12

To evaluate systemic inflammation using CRP levels.

Baseline and Week 12
Change in Interleukin-6 (pg/mL)
Zeitfenster: Baseline and Week 12

To measure inflammatory status via IL-6 concentration.

Baseline and Week 12
Change in Fatigue (FACIT-F Questionnaire Score)
Zeitfenster: Baseline and Week 12

Description: Fatigue will be assessed using the Functional Assessment of Chronic Illness Therapy - Fatigue Scale (FACIT-F). This questionnaire consists of 13 items rated on a 5-point Likert scale ranging from 0 ("not at all") to 4 ("very much"), reflecting fatigue experienced during the past 7 days. The total score is calculated by summing the item scores (after reverse scoring where applicable). Range: 0-52. Interpretation: Higher scores indicate less fatigue and therefore a better functional status, while lower scores reflect greater fatigue severity.

Baseline and Week 12
Change in Sleep Quality (PSQI Total Score)
Zeitfenster: Baseline and Week 12

Description: Sleep quality will be assessed using the Pittsburgh Sleep Quality Index (PSQI), a 19-item self-reported questionnaire that evaluates sleep quality and disturbances over the previous month. The items are grouped into seven components (subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medication, and daytime dysfunction), each scored from 0 to 3. The global PSQI score is the sum of the components (range 0-21). Range: 0-21. Interpretation: Higher scores indicate poorer sleep quality.

Baseline and Week 12
Change in Physical Activity Level (IPAQ Total Score)
Zeitfenster: Baseline and Week 12

Description: Physical activity levels will be evaluated using the International Physical Activity Questionnaire - Short Form (IPAQ-SF), which records the frequency and duration of walking, moderate, and vigorous activities over the past 7 days. The results are expressed as total metabolic equivalent minutes per week (MET-min/week) and can be categorized into three levels: low, moderate, or high activity. Range: 0 to unlimited MET-min/week. Interpretation: Higher scores indicate higher physical activity levels.

Baseline and Week 12
Change in Dietary Adherence (Mediterranean Diet Adherence Screener Score)
Zeitfenster: Baseline and Week 12

Description: Adherence to the Mediterranean diet will be assessed using the PREDIMED Questionnaire, a validated 14-item questionnaire evaluating key dietary habits such as olive oil use, fruit and vegetable consumption, fish intake, and limitation of red meat and sweets. Each affirmative answer scores 1 point, yielding a total score from 0 (minimal adherence) to 14 (maximal adherence). Range: 0-14. Interpretation: Higher scores indicate better adherence to the Mediterranean dietary pattern.

Baseline and Week 12

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

1. September 2023

Primärer Abschluss (Tatsächlich)

31. Dezember 2025

Studienabschluss (Tatsächlich)

30. Juni 2026

Studienanmeldedaten

Zuerst eingereicht

25. November 2025

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

8. Dezember 2025

Zuerst gepostet (Tatsächlich)

10. Dezember 2025

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

5. Oktober 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

2. Oktober 2026

Zuletzt verifiziert

1. Februar 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Andere Studien-ID-Nummern

  • UA-2025-06-13

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .